We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current EYPT market cap is 510.52M. The company's latest EPS is USD -1.0373 and P/E is -7.22.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 15.2M | 14.03M | 11.68M | 9.48M | 10.52M |
| Operating Income | -14.93M | -16.35M | -33.32M | -34.55M | -32.75M |
| Net Income | -12.61M | -14.1M | -29.28M | -30.83M | -29.36M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 20.37M | 34.44M | 36.94M | 41.4M | 46.02M |
| Operating Income | -47.86M | -37.29M | -55.28M | -99.64M | -75.07M |
| Net Income | -56.79M | -45.39M | -58.42M | -102.25M | -70.8M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 160.04M | 355.18M | 329.25M | 324.25M | 300.92M |
| Total Liabilities | 101.42M | 88.86M | 79.31M | 95.94M | 82.18M |
| Total Equity | 58.62M | 266.32M | 249.93M | 228.31M | 218.73M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 72.97M | 91.72M | 263.37M | 180.36M | 355.18M |
| Total Liabilities | 64.64M | 73.18M | 78.99M | 83.99M | 88.86M |
| Total Equity | 8.33M | 18.54M | 184.38M | 96.37M | 266.32M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 24.98M | 1.88M | -31.17M | -51.35M | -90.38M |
| Investing | 43.83M | -3.32M | 20.81M | -139.59M | -123.39M |
| Financing | -31.42M | 187.07M | 115k | 444k | 12.34M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -56.7M | -14.44M | -50.1M | -65.01M | 1.88M |
| Investing | -213k | -362k | -33.12M | -17.27M | -3.32M |
| Financing | 33.86M | 37.49M | 216.9M | -690k | 187.07M |
| Market Cap | 510.52M |
| Price to Earnings Ratio | -7.22 |
| Price to Sales Ratio | 11.11 |
| Price to Cash Ratio | 1.82 |
| Price to Book Ratio | 1.92 |
| Dividend Yield | - |
| Shares Outstanding | 68.25M |
| Average Volume (1 week) | 875.85k |
| Average Volume (1 Month) | 940.44k |
| 52 Week Change | -65.53% |
| 52 Week High | 30.99 |
| 52 Week Low | 6.91 |
| Spread (Intraday) | 0.18 (2.41%) |
| Company Name | EyePoint Pharmaceuticals Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.eyepointpharma.com |
| Industry | lab analytical instruments (3826) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
